Barclays predicts stock rally for weight-loss drug maker and Activision Blizzard, while BMO warns of struggles for video game stock.
TL;DR Summary
Shares of a weight-loss drug maker have risen by 20% this year, and Barclays predicts that the stock will continue to rise. The company's weight-loss drug has shown promising results in clinical trials, leading to increased investor interest and potential for growth in the market.
- This weight-loss drug maker's stock is up 20% this year — and Barclays sees it going higher CNBC
- Thursday's biggest analyst calls on Wall Street CNBC
- Barclays says there's a big buying opportunity in Activision Blizzard after blocked Microsoft deal, sees shares rallying 30% CNBC
- This video game stock could struggle after the blocking of Microsoft's Activision Blizzard takeover, BMO says CNBC
- One online retailer will get a sizable sales boost from Bed Bath & Beyond's demise, Telsey Group estimates CNBC
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
0 min
vs 1 min read
Condensed
-5%
43 → 45 words
Want the full story? Read the original article
Read on CNBC